Third Quarter Total Revenue Increased 50 Percent to $39.9 Million
Third Quarter Product and Service Revenue Increased 34 Percent to $35.3 Million Driven by COVID-19 Testing
GAAP Net Loss in the Third Quarter Was $6.0 Million; Non-GAAP Net Income Was $2.5 Million
South San Francisco, Ca — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the third quarter ended September 30, 2020.
Third Quarter 2020
Third quarter revenue increased 50.4 percent to $39.9 million from $26.5 million in the third quarter of 2019. Product and service revenue increased 34.4 percent to $35.3 million. Microfluidics product and service revenue increased 88 percent driven by COVID-19 testing. Total revenue included $4.5 million of other revenue.
GAAP net loss for the quarter was $6.0 million, compared with a GAAP net loss of $12.9 million for the third quarter of 2019.
Non-GAAP net income was $2.5 million for the quarter, compared with a $6.2 million non-GAAP net loss for the third quarter of 2019.
“I am extremely pleased with our exceptional performance this quarter with strong execution on our COVID-19 testing and clinical research strategies yielding sequential growth for both the microfluidics and mass cytometry businesses,” said Chris Linthwaite, President and CEO. “FDA Emergency Use Authorization of the Advanta™ Dx SARS-CoV-2 RT-PCR Assay at the end of August drove growing awareness and healthy adoption of saliva-based testing, with new instrument placements across multiple customer segments including clinical and public health labs, and academic medical centers.”
“In the third quarter, we closely managed our cash and operating expenses while making progress on milestones tied to collaboration payments,” added Linthwaite. “Moving forward, we are focused on expanding our diagnostic reach as our customers utilize microfluidics to address the gap in COVID-19 testing capacity. Longer-term, we are also executing on a product roadmap for microfluidics and mass cytometry to drive growth from translational and clinical research and diagnostics customer segments.”
A reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this news release.
Third Quarter 2020 Results
Revenue by category:
Category Revenue by Category Year-over-Year Change % of Total Revenue
Instruments $12.7 million 38% 32%
Consumables $16.6 million 44% 42%
Service $6.1 million 9% 15%
Other $4.5 million N/A 11%
Product and service revenue by market:
Mass cytometry product and service revenue decreased 3 percent to $15.1 million from $15.5 million in the prior year period due to lower sales of instruments, partially offset by higher sales of consumables and services.
Microfluidics product and service revenue increased 88 percent to $20.2 million from $10.7 million in the prior year period primarily due to higher sales of instruments and consumables.
Revenue by geographic area:
Geographic Area Revenue by Geography Year-over-Year Change % of Total Revenue
Americas* $23.7 million 113% 60%
EMEA $8.8 million (3)% 22%
Asia-Pacific $7.4 million 17% 18%
*Americas geographic area includes Other Revenue of $4.5 million
Product and service margin:
Product and service margin was 58.9 percent in the third quarter of 2020 compared to 52.6 percent in the year ago period and 52.5 percent in the second quarter of 2020. Non-GAAP product and service margin was 68.3 percent in the third quarter of 2020 compared to 65.2 percent in the year ago period and 67.1 percent in the second quarter of 2020.
The year-over-year increase in non-GAAP product and service margin was primarily due to sales of COVID-19 related consumables and lower inventory reserves. The increase was partially offset by a higher mix of microfluidics instruments, as well as lower prices and lower product volumes for mass cytometry instruments. On a sequential basis, the increase in non-GAAP product and service margin was primarily due to sales of COVID-19 related consumables partially offset by a higher mix of microfluidics instruments.
GAAP product and service margin, both sequentially and on a year-over-year basis, was positively impacted by fixed amortization over higher revenue in addition to the factors described above.
Cash and cash equivalents, and restricted cash as of September 30, 2020:
Cash and cash equivalents and restricted cash as of September 30, 2020 totaled $73.4 million, including approximately $20 million of net proceeds from sales of common stock under an “at the market” equity offering program and $10 million of unspent milestone payments under our National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) contract. Cash and cash equivalents, available for sale securities, and restricted cash as of September 30, 2019 totaled $64.8 million.
Operational and Business Progress
Microfluidics and COVID-19 testing progress
Received FDA Emergency Use Authorization (EUA) for the saliva-based Advanta™ Dx SARS-CoV-2 RT-PCR Assay for COVID-19 on August 25.
Achieved initial milestone for $11.7 million payment under NIH RADx agreement; executed definitized contract with NIH RADx.
Sold 795,000 COVID-19 assays in the third quarter.
Sold more than 30 Biomark™ HD instruments in the third quarter.
Year-to-date, 43 Biomark HD instruments have been enabled for COVID-19 testing.
Announced an agreement with Healthvana Inc. to provide clinical laboratory customers utilizing the Fluidigm® saliva-based Advanta Dx SARS-CoV-2 RT-PCR Assay with the option to deliver test results faster via Healthvana’s mobile platform.
Introduced the Fluidigm COVID-19 Campus Safeguard Program to support saliva-based testing needs for U.S. colleges and universities, with participation already at Oklahoma University, University of Pennsylvania, and Washington University in St. Louis.
Fluidigm COVID-19 testing adopted by clinical labs and public health and academic medical centers including: Dante Labs in Europe; Millennium Health, which has partnered with the U.S. Health and Human Service to provide surge testing through the federal Community-Based Testing Site program; hospitals in Greece; ImmunoGenomics; and Vero Diagnostics.
Mass Cytometry and Imaging Mass Cytometry Progress
Record sales of the Maxpar® Direct™ Immune Profiling Assay™ for COVID-19 immune profiling studies.
Launch of a new Innovative Solutions offering by Fluidigm Therapeutic Insights Services, the robust IMC™ Cell Segmentation Kit, which facilitates an end-to-end workflow for Imaging Mass Cytometry™ (IMC) single-cell data analytics.
Use of CyTOF® technology in 16 COVID-19 publications and five COVID-19 clinical trials through September.
Use of CyTOF technology in 113 National Clinical Trials through September, including 25 initiated in 2020, with three of those utilizing Imaging Mass Cytometry. Total publications and reviews involving CyTOF technology exceeded 1,300, including 65 that involved Imaging Mass Cytometry.
Conference Call Information
Fluidigm will host a conference call today, November 5, 2020, at 2:00 p.m. PT, 5:00 p.m. ET, to discuss third quarter 2020 financial results and operational progress. Individuals interested in listening to the conference call may do so by dialing the following:
US domestic callers: (877) 556-5248
Outside US callers: (720) 545-0029
Please reference Conference ID: 7187059
A live webcast of the conference call will be available online from the Investor Relations page of the company’s website at Events & Presentations. The link will not be active until 1:45 p.m. PT, 4:45 p.m. ET, on November 5, 2020.
After the live webcast, the call will be archived on Fluidigm’s Investor Relations page at investors.fluidigm.com. In addition, a telephone replay of the teleconference will be available approximately 90 minutes after the end of the call.
The replay dial-in numbers are:
US domestic callers: (855) 859-2056
Outside US: (404) 537-3406
Please reference Conference ID: 7187059
The telephone replay will be available until November 12.
Statement Regarding Use of Non-GAAP Financial Information
Fluidigm has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis for the three-month periods ended September 30, 2020, and September 30, 2019. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Fluidigm encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding opportunities for Fluidigm technology and products, including growth from sales of Fluidigm’s diagnostic tests, increasing adoption of such tests, and a product roadmap encompassing new customer segments. Forwardlooking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; the suitability and acceptance of our tools and technology by the research community pursuing solutions for the novel coronavirus pandemic; our ability and/or the ability of the institutions utilizing our products and technology to obtain FDA and any other requisite approvals to use our products and technology for diagnostic testing purposes; customers and prospective customers continuing to curtail or suspend activities utilizing our products; interruptions or delays in the supply of components or materials for, or manufacturing of, our products resulting from the pandemic or other factors; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to reliance on sales of capital equipment for a significant proportion of revenues in each quarter; potential product performance and quality issues; the possible loss of key employees, customers, or suppliers; intellectual property risks; competition; uncertainties in contractual relationships; risks relating to company research and development, sales, marketing, and distribution plans and capabilities; reductions in research and development spending or changes in budget priorities by customers; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks and uncertainties and other information affecting Fluidigm’s business and operating results is contained in its Annual Report on Form 10-K for the year ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, Advanta, Biomark, CyTOF, Direct, Imaging Mass Cytometry, IMC, Immune Profiling Assay, and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Post based on press release from Fluidigm Corporation to Zennie62Media, Inc.
You may also like
Oakland News Now Recent Posts
- Cal Football: Femi Oladejo Press Conference (10.19.21) October 19, 2021
- Cal Football: Justin Wilcox Press Conference (10.19.21) October 19, 2021
- Robert Bob Hamilton Oakland, Commercial Real Estate And Friend To Many, Died October 9th October 19, 2021
- All Passengers, Crew Safe After Plane Crashes In Texas Field October 19, 2021
- Why Vish was So Impressed with 49ers QB Trey Lance’s First Start October 19, 2021
- San Francisco 49ers News & Rumors On DeForest Buckner, 49ers Injury Report, Trade Candidates | Q&A October 19, 2021
- MINOR LEAGUE PLAYERS HAVE A PLACE TO LIVE || Starting 9 October 19, 2021
- Las Vegas Raiders Maxx Crosby Early Candidate For Defense Player Of The Year By Eric Pangilinan October 19, 2021
- San Francisco, Tourism Industry Offer Cash Rewards To Stop Auto Burglary Fencing Operations October 19, 2021
- 882 Alma Pl, Oakland, CA, 94610 October 19, 2021
- Joel Embiid press conference after Ben Simmons was suspended during Sixers practice October 19, 2021
- The Offset Jim Interview: Coming Up in Oakland, Rich Off The Pack, Moving to NYC & More October 19, 2021
- CBS Correspondent Takes a Flying Car Up for a Spin October 19, 2021
- Meet Maxx Crosby’s Rescue Pit Bulls | Episode 2 | Crosby’s Crib | Raiders | NFL October 19, 2021
- TikTok star robbed at gunpoint in San Francisco October 19, 2021
- Top 15 Plays of Week 6 | NFL 2021 Highlights October 19, 2021
- Google Event 2021 Reaction: Pixel 6 Pro Launch October 19, 2021
- All-Access with the Golden State Warriors Veterans October 19, 2021
- Neighbor rescues man from burning home in San Francisco October 19, 2021
- The 1991 Oakland Hills Fire October 19, 2021
- Seahawks Trade Rumors: 4 Players Who Could Get Dealt Before The NFL Trade Deadline Ft. Quandre Diggs October 19, 2021
- Las Vegas Raiders My Apology Amari Cooper Didn’t Say Jon Gruden Was A Racist By Eric Pangilinan October 19, 2021
- Lake Merritt is a large tidal lagoon in the center of Oakland, California, just east of Downtown October 19, 2021
- Red Sox Fans Troll A Rod With Savage Bennifer Chants At MLB Playoffs… October 19, 2021
- CBS San Francisco: Residents Are So Upset With Crime They Are Hiring Private Security October 19, 2021
- Astros vs. Red Sox ALCS Game 3 Highlights (10/18/21) | MLB Highlights October 19, 2021
- Yet Another Bank of America, SBA EIDL Horror Story Sent For Blogging October 19, 2021
- Cowboy Bebop | Official Teaser “Lost Session” | Netflix October 19, 2021
- Cowboy Bebop | Opening Credits | Netflix October 19, 2021
- Intellectual Property Law Issues in Non Fungible Tokens (NFTs) October 19, 2021